Multidisciplinary Follow-up of Patients Treated for Malignant Hematological Disease
NCT ID: NCT03031106
Last Updated: 2018-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2017-01-31
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
NCT05224661
Early Palliative Care for Patients With Haematological Malignancies
NCT03800095
Treatment of Adult ALL With an MRD-directed Programme.
NCT00358072
Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia
NCT03697707
Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)
NCT01146977
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients followed before or after 1. line treatment
* patients in stable phase \> 6 months after 1. line treatment
* the patients participation in the study must be assessed and decided by the doctor responsible for the patient's course of treatment
Exclusion Criteria
* conditions which compromise the ability to understand the study and submit informed consent (ex.: dementia and severe mental illness / disability)
* lack of capability to fill out electronic questionnaires
* poor self-care and/or compliance
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aalborg University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mia Sommer
Clinical Research Nurse, ph.d. student
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mia Sommer, MHSc
Role: PRINCIPAL_INVESTIGATOR
Aalborg University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aalborg University Hospital, Department of Hematology
Aalborg, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TVO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.